Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Shares Outstanding (Weighted Average) (2016 - 2026)

Intellia Therapeutics has reported Shares Outstanding (Weighted Average) over the past 12 years, most recently at $118.5 million for Q1 2026.

  • Quarterly Shares Outstanding (Weighted Average) rose 14.48% to $118.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $118.5 million through Mar 2026, up 14.48% year-over-year, with the annual reading at $108.4 million for FY2025, 9.64% up from the prior year.
  • Shares Outstanding (Weighted Average) was $118.5 million for Q1 2026 at Intellia Therapeutics, up from $108.4 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $118.5 million in Q1 2026 and troughed at $74.8 million in Q1 2022.
  • The 5-year median for Shares Outstanding (Weighted Average) is $95.5 million (2024), against an average of $93.2 million.
  • Year-over-year, Shares Outstanding (Weighted Average) increased 17.42% in 2023 and then increased 6.85% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $77.0 million in 2022, then rose by 15.33% to $88.8 million in 2023, then grew by 11.35% to $98.8 million in 2024, then grew by 9.64% to $108.4 million in 2025, then increased by 9.33% to $118.5 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Shares Outstanding (Weighted Average) are $118.5 million (Q1 2026), $108.4 million (Q4 2025), and $105.8 million (Q3 2025).